Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association.

Exp Clin Endocrinol Diabetes

Diabetes-Zentrum Quakenbrück, Quakenbrück.

Published: October 2009

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0029-1239559DOI Listing

Publication Analysis

Top Keywords

medical antihyperglycaemic
4
antihyperglycaemic treatment
4
treatment type
4
type diabetes
4
diabetes mellitus
4
mellitus update
4
update evidence-based
4
evidence-based guideline
4
guideline german
4
german diabetes
4

Similar Publications

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation.

Mol Metab

January 2025

Section of Endocrinology and Investigative Medicine, Imperial College London, United Kingdom. Electronic address:

Objectives: There is renewed interest in targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) for treatment of obesity and type 2 diabetes. G-protein coupled receptor desensitisation is suggested to reduce the long-term efficacy of glucagon-like-peptide 1 receptor (GLP-1R) agonists and may similarly affect the efficacy of GIPR agonists. We explored the extent of pancreatic GIPR functional desensitisation with sustained agonist exposure.

View Article and Find Full Text PDF

Aims: To assess outcomes of oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c), where specific treatment guidance is limited.

Materials And Methods: Using hospital-linked UK primary care records (Clinical Practice Research Datalink; 2004-2020), we identified 7084 people with a pancreatic condition (acute pancreatitis, chronic pancreatitis, pancreatic cancer and haemochromatosis) preceding diabetes diagnosis (type 3c cohort), initiating oral glucose-lowering therapy (metformin, sulphonylureas, SGLT2-inhibitors, DPP4-inhibitors or thiazolidinediones), and without concurrent insulin treatment. We stratified by pancreatic exocrine insufficiency [PEI] (n = 5917 without PEI, 1167 with PEI) and matched to 97 227 type 2 diabetes (T2D) controls.

View Article and Find Full Text PDF

Aims: To investigate glycaemic control in Chinese adults with type 2 diabetes (T2D) initiating, or switching to insulin degludec/insulin aspart (IDegAsp), a co-formulation of basal, and bolus insulin, in a real-world setting.

Materials And Methods: A 20-week, prospective, single-arm, open-label, non-interventional study was conducted in Chinese adults with T2D initiating, or switching to IDegAsp after anti-hyperglycaemic treatment with oral antidiabetic drugs (OADs), other insulins, or glucagon-like peptide-1 receptor agonists. The primary endpoint was a change in HbA from baseline to end of the study; the secondary endpoints included a change in fasting plasma glucose and Diabetes Treatment Satisfaction Questionnaire (DTSQ) score.

View Article and Find Full Text PDF

Current and emerging strategies for the prevention of hepatocellular carcinoma.

Nat Rev Gastroenterol Hepatol

December 2024

Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Liver cancer is the third leading cause of cancer-related deaths globally, with incident cases expected to rise from 905,700 in 2020 to 1.4 million by 2040. Hepatocellular carcinoma (HCC) accounts for about 80% of all primary liver cancers.

View Article and Find Full Text PDF
Article Synopsis
  • Clinical practice guidelines (CPGs) for diabetes management face challenges in older adults due to factors like frailty and multiple health issues.
  • * The systematic review analyzed 23 CPGs from the last decade, focusing on HbA1c targets and treatment recommendations for older and frail individuals.
  • * Results showed most CPGs recommend stricter HbA1c targets for healthier older adults, while suggesting more lenient targets for frail individuals, though there's variability in pharmacotherapy advice, especially for frail patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!